34630 The mental health and psychosocial burden among patients living with vitiligo in the United States: Findings from the VALIANT study

Bibeau, Kristen; Gardner, John R.; Lindley, Anouk

doi:10.1016/j.jaad.2022.06.508

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that patients with vitiligo and AA are at a higher risk of developing anxiety and depression 39–41 . Our study revealed that there are a higher anxiety and depression levels among AA patients compared to vitiligo.…”

Section: Discussionsupporting

confidence: 52%

“…It has been reported that patients with vitiligo and AA are at a higher risk of developing anxiety and depression. [39][40][41] Our study revealed that there are a higher anxiety and depression levels among AA patients compared to vitiligo. However, some researchers have not found any statistically significant differences between vitiligo and AA in terms of anxiety and depression.…”

Section: Depression and Anxiety And Associated Factorsmentioning

confidence: 94%

See 1 more Smart Citation

Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients

Ghalamkarpour,

Araghi,

Tabari

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction and ObjectivesVitiligo and alopecia areata (AA) are two autoimmune skin diseases that affect patients' quality of life (QoL) and give rise to psychosocial complications, such as depression, negative self‐image, less joyful social engagements, and low self‐esteem. These two disorders have common and uncommon characteristics. Therefore, in this study, we tried to evaluate the similarities and differences in the psychological parameters including quality of life, sleep disturbance, anxiety, and depression levels between, vitiligo and AA patients.Materials and MethodsPatients with either vitiligo or AA visiting the outpatient dermatology clinic from November 2017 to December 2020 have been included in this study. Persian versions of three questionnaires including the dermatology life quality index (DLQI), hospital anxiety and depression scale (HADS), and Pittsburgh sleep quality index (PSQI), have been used to assess the QoL, sleep disturbance, anxiety, and depression levels in patients.ResultsIn total, 188 patients, including 94 (50%) cases of AA and 94 (50%) patients with vitiligo, met the criteria. In AA patients, a significantly higher DLQI score was found (p‐value = 0.002) compared to the vitiligo cases, which means a better QoL in vitiligo patients. Additionally, AA patients had higher scores of anxiety (P‐value<0.001) and depression (p‐Value<0.001). However, sleep disturbance (64.9% of AA patients vs. 59.3% of vitiligo patients; p‐Value = 0.4888) was not significantly different between the two groups.ConclusionsOur data showed lower QoL and higher levels of anxiety and depression in AA patients compared to vitiligo cases, but no difference was seen in sleep disturbance in the PSQI‐P score.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Depression and Anxiety And Associated Factorsmentioning

confidence: 94%

Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients

Ghalamkarpour,

Araghi,

Tabari

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Based on the clinical manifestations and extent of involvement, vitiligo can be generally categorized as non‐segmental, segmental, mixed, or unclassified 3 . The disease can seriously affect the mental health of patients, leading to anxiety and depression, which in turn reduce the quality of life, like psoriasis and atopic dermatitis 2,4 . Triggers for the onset of vitiligo include severe sun exposure, pregnancy, skin trauma, and mental stress.…”

Section: Introductionmentioning

confidence: 99%

“…3 The disease can seriously affect the mental health of patients, leading to anxiety and depression, which in turn reduce the quality of life, like psoriasis and atopic dermatitis. 2,4 Triggers for the onset of vitiligo include severe sun exposure, pregnancy, skin trauma, and mental stress. Its pathogenesis is thought to be related to various factors such as genetics, autoimmune diseases, and oxidative stress.…”

mentioning

confidence: 99%

Comparing the efficacy of 308‐nm light‐emitting diode and 308‐nm excimer lamp for treating vitiligo: A randomized controlled trial

Hu,

Liu,

et al. 2024

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

BackgroundIn previous studies, the 308‐nm light‐emitting diode (LED) has been proven safe and effective for treating vitiligo. However, direct comparisons between the 308‐nm LED and 308‐nm excimer lamp (308‐nm MEL) for the treatment of vitiligo are lacking.ObjectiveTo compare the efficacy of the 308‐nm LED and 308‐nm MEL for treating nonsegmental stable vitiligo.Patients and MethodsThis randomized controlled trial was conducted between January 2018 and August 2023. Enrolled patients were randomly assigned to either the 308‐nm LED or the 308‐nm MEL groups, both receiving 16 treatment sessions. Adverse events that occurred during the treatment were documented.ResultsIn total, 269 stable vitiligo patches from 174 patients completed the study. A total of 131 lesions were included in the 308‐nm LED group, and 138 lesions were included in the 308‐nm MEL group. After 16 treatment sessions, 38.17% of the vitiligo patches in the 308‐nm LED group achieved repigmentation of at least 50% versus 38.41% in the 308‐nm MEL group. The two devices exhibited similar results in terms of efficacy for a repigmentation of at least 50% (p = .968). The incidence of adverse effects with the two phototherapy devices was comparable (p = .522).ConclusionsTreatment of vitiligo with the 308‐nm LED had a similar efficacy rate to the 308‐nm MEL, and the incidence of adverse effects was comparable between the two devices.

show abstract

34630 The mental health and psychosocial burden among patients living with vitiligo in the United States: Findings from the VALIANT study

Cited by 2 publications

References 0 publications

Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients

Comparing quality of life, anxiety, depression, sleep disturbance, and associated factors in vitiligo and alopecia areata patients

Comparing the efficacy of 308‐nm light‐emitting diode and 308‐nm excimer lamp for treating vitiligo: A randomized controlled trial

Contact Info

Product

Resources

About